نتائج البحث - "Catherine Barbaroux"

المساهمون: Biologie des Tumeurs, Institut Curie [Paris], Unité de génétique et biologie des cancers (U830), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Génétique Médicale, Université Paris Descartes - Paris 5 (UPD5)-PRES Sorbonne Paris Cité, This work was supported by INCa Recherche Translationnelle grant number 4521000377, BMC, Ed., INSTITUT CURIE, Université Paris Descartes - Paris 5 (UPD5) - Institut Curie - Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5) - PRES Sorbonne Paris Cité, Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)

المصدر: BMC Cancer
BMC Cancer, 2013, 13 (1), pp.484. ⟨10.1186/1471-2407-13-484⟩
BMC Cancer, BioMed Central, 2013, 13 (1), pp.484. ⟨10.1186/1471-2407-13-484⟩
BMC Cancer, BioMed Central, 2013, 13 (1), pp.484. 〈10.1186/1471-2407-13-484〉

مصطلحات موضوعية: Cancer Research, RNA Splicing, DNA Mutational Analysis, Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gene mutation, Biology, 03 medical and health sciences, 0302 clinical medicine, Germline mutation, Breast cancer, [SDV.CAN] Life Sciences [q-bio]/Cancer, Ovarian cancer, Genetics, Genetic predisposition, medicine, Humans, Genetic Predisposition to Disease, Germ-Line Mutation, 030304 developmental biology, RAD51 paralogs, 0303 health sciences, RAD51B, Cancer, Exons, medicine.disease, Penetrance, Immunohistochemistry, 3. Good health, Pedigree, DNA-Binding Proteins, Oncology, 030220 oncology & carcinogenesis, Cancer research, RAD51C, Hereditary Breast and Ovarian Cancer Syndrome, Female, Research Article

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a00d8ab71c12dfca3a148806c4061d7a
https://www.hal.inserm.fr/inserm-00878230

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

6

Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients

المؤلفون: Véronique Scott, Nicolas Servant, David Gentien, Michel Marty, Philippe Bertheau, Frédérique Spyratos, Patricia de Cremoux, Fabien Valet, Brigitte Sigal-Zafrani, Catherine Barbaroux, Jacqueline Lehmann-Che, Marie-Christine Mathieu, Sophie Vacher, Carine Tran-Perennou, Bernard Asselain, Jean-Marc Guinebretière

المساهمون: BMC, Ed., Département de Biologie des Tumeurs, Institut Curie [Paris], Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, Mines Paris - PSL (École nationale supérieure des mines de Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de biostatistiques, Département de Recherche Translationnelle, Département de biochimie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de recherche translationnelle, Direction de la recherche [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service de Génétique Oncologique, Département de biologie et pathologie médicales [Gustave Roussy], Institut Gustave Roussy (IGR), Service d'anatomo-pathologie [Paris], Département de pathologie, Institut Curie [Paris]-Hôpital René HUGUENIN (Saint-Cloud), Centre des Innovations Thérapeutiques en Oncologie et Hématologie, This work was supported by academic grants (PHRC AOM/2OO2/02117) and industrial grants from Pfizer inc., Roche, Sanofi-Aventis.ISRCTN10059974., INSTITUT CURIE, Cancer et génôme: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, MINES ParisTech - École nationale supérieure des mines de Paris-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -INSTITUT CURIE, Département de recherche translationnelle, Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Institut Gustave Roussy ( IGR ) -Institut Gustave Roussy ( IGR ), Institut Gustave Roussy ( IGR ), INSTITUT CURIE-Hôpital René HUGUENIN (Saint-Cloud), MINES ParisTech - École nationale supérieure des mines de Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)

المصدر: BMC Cancer
BMC Cancer, 2011, 11 (1), pp.215. ⟨10.1186/1471-2407-11-215⟩
BMC Cancer, Vol 11, Iss 1, p 215 (2011)
BMC Cancer, BioMed Central, 2011, 11 (1), pp.215. 〈10.1186/1471-2407-11-215〉
BMC Cancer, BioMed Central, 2011, 11 (1), pp.215. ⟨10.1186/1471-2407-11-215⟩

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_treatment, quality criteria, MESH : Breast Neoplasms, Bioinformatics, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Transcriptome, 0302 clinical medicine, Reference genes, MESH: Reverse Transcriptase Polymerase Chain Reaction, Cluster Analysis, Medicine, MESH : Female, Neoadjuvant therapy, 0303 health sciences, neoadjuvant setting, Reverse Transcriptase Polymerase Chain Reaction, MESH: Research Design, MESH : Reverse Transcriptase Polymerase Chain Reaction, MESH : Chemotherapy, Adjuvant, MESH: Gene Expression Regulation, Neoplastic, MESH : Research Design, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Neoadjuvant Therapy, 3. Good health, Gene Expression Regulation, Neoplastic, MESH: Reproducibility of Results, MESH : Antineoplastic Agents, Chemotherapy, Adjuvant, Research Design, MESH: Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Research Article, medicine.medical_specialty, MESH : Gene Expression Regulation, Neoplastic, MESH: Neoadjuvant Therapy, Antineoplastic Agents, Breast Neoplasms, Context (language use), [SDV.CAN]Life Sciences [q-bio]/Cancer, RNA integrity number, lcsh:RC254-282, 03 medical and health sciences, MESH: Gene Expression Profiling, Breast cancer, breast cancer, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Genetics, Humans, MESH : Cluster Analysis, 030304 developmental biology, MESH: Humans, business.industry, Gene Expression Profiling, MESH : Gene Expression Profiling, MESH : Reproducibility of Results, MESH : Humans, RT-qPCR, Reproducibility of Results, RNA, medicine.disease, MESH: Cluster Analysis, Gene expression profiling, MESH: Antineoplastic Agents, business, MESH : Neoadjuvant Therapy, transcriptome, MESH: Female, MESH: Breast Neoplasms